Skip to main content

Table 1 Currently available agents against the IGF pathway evaluated in clinical trials for the treatment of HCC

From: The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Compound Company Mechanism of action Phase of clinical development Trial Status Intervention Type of Cancer
MEDI-573 MedImmune LLC Fully Human mAb anti- IGF1 and –IGF2 1b/2 Completed In combination with sorafenib Unresectable or metastatic HCC
IMC-A12 National Cancer Institute Fully Recombinant Human mAb anti- IGF1R 2 Completed Alone Adult Primary, advanced, localized unresectable, recurrent HCC
  National Cancer Institute   1 Active, not recruiting In combination with sorafenib tosylate Advanced HCC
  Eli Lilly and Company   2 Active, not recruiting In combination with sorafenib Advanced HCC
BIIB-022 BiogenIdec Human IgG4P nonglycosylated antibody anti-IGF1R 1b Completed In combination with sorafenib Advanced HCC
AVE-1640 Sanofi-Aventis Humanized mAb anti- IGF1R 1/2 Completed Alone and in combination with sorafenib and erlotinib HCC not eligible for local treatment
OSI-906 AstellasPharmaInc Small molecule inhibitor of IGF1R 2 Completed Alone With advanced HCC after failure of first-line treatment with sorafenib
  1. Data from clinicaltrials.gov.